Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p72
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 72/162)
Character Range: 15031139–15037768

the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or
                                                                                                         Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND
                                                                                                         The treatment must provide no more than the balance of up to 16 weeks treatment; AND
                                                                                                         Must be treated by a rheumatologist.  or
                                                                                                         Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.
C14228              P14228         CN14228          Calcium                                              Hyperphosphataemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Compliance with Authority Required procedures - Streamlined Authority Code 14228
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                         The condition must be associated with chronic renal failure.
C14229              P14229         CN14229          Mesalazine                                           Crohn disease
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C14231              P14231         CN14231          Calcitriol                                           Hypophosphataemic rickets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 14231
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C14234              P14234         CN14234          Risedronic acid                                      Corticosteroid-induced osteoporosis
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                         Patient must currently be on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy; AND
                                                                                                         Patient must have a Bone Mineral Density (BMD) T-score of -1.5 or less; AND
                                                                                                         Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                         The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.
C14235              P14235         CN14235          Risedronic acid                                      Osteoporosis
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient;
                                                                                                         Patient must be aged 70 years or older;
                                                                                                         Patient must have a Bone Mineral Density (BMD) T-score of -2.5 or less; AND
                                                                                                         Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                         The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.
C14236              P14236         CN14236          Calcipotriol with betamethasone                      Chronic stable plaque type psoriasis vulgaris
                                                                                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable